Author:
ATAYIK Emel,AYTEKİN Gökhan
Publisher
Journal of Emergency Medicine Case Reports
Reference10 articles.
1. 1. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. PubMed PMID: 32350134; PubMed Central PMCID: PMCPMC7245089.
2. 2. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. PubMed PMID: 32083985; PubMed Central PMCID: PMCPMC7233368.
3. 3. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248. PubMed PMID: 32161940; PubMed Central PMCID: PMCPMC7108125.
4. 4. Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403. PubMed PMID: 29069471; eng.
5. 5. Worm M, Eckermann O, Dolle S, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int. 2014 May 23;111(21):367-75. doi: 10.3238/arztebl.2014.0367. PubMed PMID: 24939374; PubMed Central PMCID: PMCPMC4075276.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献